全文获取类型
收费全文 | 3379篇 |
免费 | 267篇 |
国内免费 | 16篇 |
专业分类
耳鼻咽喉 | 37篇 |
儿科学 | 85篇 |
妇产科学 | 89篇 |
基础医学 | 324篇 |
口腔科学 | 53篇 |
临床医学 | 280篇 |
内科学 | 1045篇 |
皮肤病学 | 94篇 |
神经病学 | 230篇 |
特种医学 | 95篇 |
外科学 | 587篇 |
综合类 | 83篇 |
一般理论 | 1篇 |
预防医学 | 177篇 |
眼科学 | 62篇 |
药学 | 153篇 |
中国医学 | 20篇 |
肿瘤学 | 247篇 |
出版年
2024年 | 3篇 |
2023年 | 54篇 |
2022年 | 112篇 |
2021年 | 250篇 |
2020年 | 154篇 |
2019年 | 181篇 |
2018年 | 229篇 |
2017年 | 136篇 |
2016年 | 127篇 |
2015年 | 117篇 |
2014年 | 170篇 |
2013年 | 206篇 |
2012年 | 286篇 |
2011年 | 259篇 |
2010年 | 158篇 |
2009年 | 101篇 |
2008年 | 160篇 |
2007年 | 188篇 |
2006年 | 169篇 |
2005年 | 140篇 |
2004年 | 131篇 |
2003年 | 98篇 |
2002年 | 95篇 |
2001年 | 12篇 |
2000年 | 14篇 |
1999年 | 10篇 |
1998年 | 8篇 |
1997年 | 7篇 |
1996年 | 8篇 |
1995年 | 11篇 |
1994年 | 8篇 |
1993年 | 13篇 |
1992年 | 7篇 |
1991年 | 4篇 |
1990年 | 4篇 |
1989年 | 6篇 |
1988年 | 6篇 |
1986年 | 1篇 |
1985年 | 2篇 |
1984年 | 3篇 |
1983年 | 2篇 |
1981年 | 1篇 |
1979年 | 1篇 |
1978年 | 1篇 |
1977年 | 1篇 |
1974年 | 2篇 |
1970年 | 1篇 |
1961年 | 1篇 |
1943年 | 1篇 |
1923年 | 2篇 |
排序方式: 共有3662条查询结果,搜索用时 15 毫秒
101.
102.
Buxbaum JL Jhala NC Christein JD Eloubeidi MA 《Gastrointestinal endoscopy》2012,75(4):898-9; discussion 898-9
103.
Mouse genetic engineering has revolutionized our understanding of the molecular and genetic basis of heart development and disease. This technology involves conditional tissue-specific and temporal transgenic and gene targeting approaches, as well as introduction of polymorphisms into the mouse genome. These approaches are increasingly used to elucidate the genetic pathways underlying tissue homeostasis, physiology, and pathophysiology of adult heart. They have also led to the development of clinically relevant models of human cardiac diseases. Here, we review the technologies and their limitations in general and the cardiovascular research community in particular. 相似文献
104.
Manetti M Allanore Y Saad M Fatini C Cohignac V Guiducci S Romano E Airó P Caramaschi P Tinazzi I Riccieri V Della Rossa A Abbate R Caporali R Cuomo G Valesini G Dieudé P Hachulla E Cracowski JL Tiev K Letenneur L Amouyel P Lambert JC Chiocchia G Martinez M Ibba-Manneschi L Matucci-Cerinic M 《Annals of the rheumatic diseases》2012,71(6):1034-1041
105.
Tserendorj Munkhjargal Mahmoud AbouLaila Mohamad Alaa Terkawi Thillaiampalam Sivakumar Madoka Ichikawa Batdorj Davaasuren Tserendorj Nyamjargal Naoaki Yokoyama Ikuo Igarashi 《The American journal of tropical medicine and hygiene》2012,87(4):681-688
We evaluated the inhibitory effects of pepstatin A and mefloquine on the in vitro and in vivo growths of Babesia parasites. The in vitro growth of Babesia bovis, B. bigemina, B. caballi, and B. equi was significantly inhibited (P < 0.05) by micromolar concentrations of pepstatin A (50% inhibitory concentrations = 38.5, 36.5, 17.6, and 18.1 μM, respectively) and mefloquine (50% inhibitory concentrations = 59.7, 56.7, 20.7, and 4 μM, respectively). Furthermore, both reagents either alone at a concentration of 5 mg/kg or in combinations (2.5/2.5 and 5/5 mg/kg) for 10 days significantly inhibited the in vivo growth of B. microti in mice. Mefloquine treatment was highly effective and the combination treatments were less effective than other treatments. Therefore, mefloquine may antagonize the actions of pepstatin A against babesiosis and aspartic proteases may play an important role in the asexual growth cycle of Babesia parasites. 相似文献
106.
Schmid C Labopin M Nagler A Niederwieser D Castagna L Tabrizi R Stadler M Kuball J Cornelissen J Vorlicek J Socié G Falda M Vindeløv L Ljungman P Jackson G Kröger N Rank A Polge E Rocha V Mohty M;Acute Leukaemia Working Party of the European Group for Blood Marrow Transplantation 《Blood》2012,119(6):1599-1606
Because information on management and outcome of AML relapse after allogeneic hematopoietic stem cell transplantation (HSCT) with reduced intensity conditioning (RIC) is scarce, a retrospective registry study was performed by the Acute Leukemia Working Party of EBMT. Among 2815 RIC transplants performed for AML in complete remission (CR) between 1999 and 2008, cumulative incidence of relapse was 32% ± 1%. Relapsed patients (263) were included into a detailed analysis of risk factors for overall survival (OS) and building of a prognostic score. CR was reinduced in 32%; remission duration after transplantation was the only prognostic factor for response (P = .003). Estimated 2-year OS from relapse was 14%, thereby resembling results of AML relapse after standard conditioning. Among variables available at the time of relapse, remission after HSCT > 5 months (hazard ratio [HR] = 0.50, 95% confidence interval [CI], 0.37-0.67, P < .001), bone marrow blasts less than 27% (HR = 0.53, 95% CI, 0.40-0.72, P < .001), and absence of acute GVHD after HSCT (HR = 0.67, 95% CI, 0.49-0.93, P = .017) were associated with better OS. Based on these factors, 3 prognostic groups could be discriminated, showing OS of 32% ± 7%, 19% ± 4%, and 4% ± 2% at 2 years (P < .0001). Long-term survival was achieved almost exclusively after successful induction of CR by cytoreductive therapy, followed either by donor lymphocyte infusion or second HSCT for consolidation. 相似文献
107.
Al-Kali A Konoplev S Lin E Kadia T Faderl S Ravandi F Ayoubi M Brandt M Cortes JE Kantarjian H Borthakur G 《Haematologica》2012,97(2):235-240
Background
The hypocellular variant of acute myeloid leukemia accounts for less than 10% of all cases of adult acute myeloid leukemia. It is defined by having less than 20 percent of cellular bone marrow in a biopsy at presentation. It is unclear in the literature whether the outcome of hypocellular acute myeloid leukemia differs from that of non-hypocellular acute myeloid leukemia.Design and Methods
We retrospectively analyzed all the cases reported to be hypocellular acute myeloid leukemia between 2000 and 2009. A second pathology review was conducted and the diagnosis was confirmed in all cases.Results
One hundred twenty-three (9%) patients were identified: patients with hypocellular acute myeloid leukemia were older than those with non-hypocellular acute myeloid leukemia (P=0.009) and more frequently presented with cytopenias (P<0.001). Forty-one patients with hypocellular acute myeloid leukemia had an antecedent hematologic disorder and 11 patients had received prior chemo-radiotherapy for non-hematopoietic neoplasms. On multivariate analysis, overall survival, remission duration and event-free survival were comparable to those of other patients with acute myeloid leukemia.Conclusions
The outcome of hypocellular acute myeloid leukemia does not differ from that of non-hypocellular acute myeloid leukemia. 相似文献108.
Fabre C Koscielny S Mohty M Fegueux N Blaise D Maillard N Tabrizi R Michallet M Socié G Yakoub-Agha I Garban F Uzunov M François S Contentin N Lapusan S Bourhis JH 《Haematologica》2012,97(4):482-490
Background
How tandem autologous-allogeneic stem cell transplantation should be integrated in the treatment of multiple myeloma remains controversial. We examined the long-term outcome of patients with multiple myeloma managed with tandem autologous-allogeneic stem cell transplantation and present a prognostic factor analysis based on the experience of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).Design and Methods
This French, retrospective, registry-based study included 146 patients who had undergone tandem autologous-allogeneic transplantation for multiple myeloma at 20 SFGM-TC centers between 1998 and 2010. The patients included in the study had fully completed the two steps of a planned tandem autologous-allogeneic transplantation. No treatment had to be administered between the autologous and allogeneic parts of the tandem procedure.Results
Seventy-seven patients (53%) underwent tandem autologous-allogeneic transplantation as part of upfront treatment, i.e. after a single line of treatment not including autologous transplantation. The median follow-up from the allogeneic transplant was 47.5 months (range, 1.2–132 months). At 4 years, the overall survival and event-free survival rates were 48% (95% CI 39–57 %) and 27% (95% CI 19–36), respectively. Eighteen patients (12%) experienced grade III–IV acute graft-versus-host disease and 43 patients (30%) had chronic graft-versus-host disease. The transplant-related mortality rate at 1 year was 15% (95% CI 10–22). Patients receiving tandem transplantation as upfront treatment had significantly improved event-free survival (36% versus 11%; P=0.005) and overall survival (56% versus 34%; P=0.02). Donor’s age ≤50 years was associated with improved event-free survival (35% versus 16%; P=0.005) and overall survival (54% versus 41%; P=0.02). In the multivariable analysis, upfront tandem transplantation, donor’s age ≤50 years and full chimerism were independent prognostic factors for better outcome.Conclusions
We confirmed the feasibility of tandem autologour-allogeneic transplantation in heavily treated patients with multiple myeloma. We identified younger donor’s age and upfront tandem transplantation as two independent prognostic factors for survival which could be further explored in prospective studies. 相似文献109.